Phase 3
N=15
Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals
HIV-1-infection
Bottom Line
View on ClinicalTrials.gov: NCT04079452 ↗Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Apr 2022
Primary outcome: Primary: Total Doravirine Concentrations in Cerebrospinal Fluid — 58.6 ng/ml
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Doravirine (Drug); Descovy (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- Primary completion
- Aug 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Doravirine Concentrations in Cerebrospinal Fluid |
58.6 | — |
| PRIMARY Total Doravirine Concentrations in Blood Plasma |
417.6 | — |
| PRIMARY Total Doravirine Concentration CSF/Plasma Ratio |
0.13 | — |
| PRIMARY HIV-1 RNA in Cerebrospinal Fluid |
13 | — |
| PRIMARY HIV-1 RNA in Blood Plasma |
14 | — |
| PRIMARY Unbound Doravirine Concentrations in CSF |
44.6 | — |
| PRIMARY Doravirine Concentrations in Blood Plasma |
53.5 | — |
| PRIMARY Unbound Doravirine Concentration CSF/Plasma Ratio |
0.99 | — |
Summary
Doravirine is a new HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) that has demonstrated a good efficacy and safety profile in clinical trials. It functions by inhibiting viral replication of both wild-type virus and most common NNRTI variants. It is dosed orally once daily and always given in combination with other HIV-1 active agents as part of highly active antiretroviral therapy. Initial pharmacokinetic studies demonstrated not extensive binding to plasma proteins, which may be crucial determinant for penetration to different reservoirs such as the central nervous system (CNS). This study will address two important issues: The pharmacokinetic profile of Doravirine in cerebrospinal fluid (CSF) as well as the maintenance of HIV suppression in CSF. The assessment of concentrations as well as the antiviral activity of new antiretroviral drugs in compartments such as CNS is relevant to avoid HIV-related neurocognitive disorders as well as for future cure strategies. In addition, the role of unbound ARV drug concentrations has been scarcely evaluated.
Eligibility Criteria
Inclusion Criteria
- Asymptomatic, HIV-1 infected individuals ≥ 18 years of age
- Be on a stable ART continously or ≥3 consecutive months preceding the screening visit. Patients already receiving TAF/FTC+DoravirineC for at least three consecutive months will be eligible.
- Plasma HIV-1 RNA at screening <40 copies/mL for at least 3 months at the Screening visit.
- Signed and dated written informed consent prior to inclusion.
- Subjects must agree to utilize a highly effective method of contraception during heterosexual intercourse from the screening visit throughout the duration of the study.
Exclusion Criteria
- Severe hepatic impairment (Child-Pugh Class C)
- Ongoing malignancy
- Active opportunistic infection
- Primary resistance to any of the ARV included in the study or history of virologic failure with risk of resistance selection to any of the study drugs.
- Any verified Grade 4 laboratory abnormality
- ALT or AST ≥ 3xULN and/or bilirubin ≥ 1.5xULN
- Adequate renal function: Estimated glomerular filtration rate ≥ 50 mL/min
- Females who are pregnant (as confirmed by positive serum pregnancy test) or breastfeeding.
- Current treatment with antiaggregant or anticoagulant therapy.
- History of any neurologic disease/condition/treatment may alter the blood brain barrier permeability.
Data sourced from ClinicalTrials.gov (NCT04079452). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.